Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 93, Issue 11, Pages 2645-2668Publisher
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.20178
Keywords
-
Funding
- NHLBI NIH HHS [HL67347] Funding Source: Medline
- NIAID NIH HHS [AI60687] Funding Source: Medline
Ask authors/readers for more resources
The U.S. Food and Drug administration (FDA) has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies, antibody fragments, antibody fusion proteins, etc.). These drugs, which may be considered as a diverse group of therapeutic proteins, are associated with several interesting pharmacokinetic characteristics. Saturable binding with target antigen may influence antibody disposition, potentially leading to nonlinear distribution and elimination. Independent of antigen interaction, concentration-dependent elimination may be expected for IgG antibodies, due to the influence of the Brambell receptor, FcRn, which protects IgG from catabolism. Antibody administration may induce the development of an endogenous antibody response, which may alter the pharmacokinetics of the therapeutic antibody. Additionally, the pharmacodynamics of antibodies are also complex; these drugs may be used for a wide array of therapeutic applications, and effects may be achieved by a variety of mechanisms. This article provides an overview of many of the complexities associated with antibody pharmacokinetics and pharmacodynamics. (C) 2004 Wiley-Liss, Inc. and the American Pharmacists Association.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available